Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

BPC-157 + TB-500 20mg Blend Dosage Protocol | PeptideDosages.com

BPC-157 + TB-500 (20 mg Blend) Dosage Protocol BPC-157 + TB-500 Dosage Chart The BPC-157 + TB-500 peptide blend is dosed at 250 mcg–500 mcg daily via subcutaneous injection in educational protocols. A 20 mg blend reconstituted with bacteriostatic water yields

By Recovery & Performance Peptides Editorial Team

BPC-157 + TB-500 (20 mg Blend) Dosage Protocol

BPC-157 + TB-500 Dosage Chart

The BPC-157 + TB-500 peptide blend is dosed at 250 mcg–500 mcg daily via subcutaneous injection in educational protocols. A 20 mg blend reconstituted with bacteriostatic water yields about 6.67 mg/mL. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water → ~6.67 mg/mL total concentration (~3.33 mg/mL of each peptide).

Typical daily range: 250–500 mcg BPC-157 + 250–500 mcg TB-500 (500–1,000 mcg total blend) once daily.

Easy measuring: At 6.67 mg/mL total, 1 unit = 0.01 mL ≈ 66.7 mcg total (~33.3 mcg of each peptide) on a U-100 insulin syringe.

Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 14 days.

BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide fragment derived from human gastric juice, studied for its cytoprotective and tissue-repair properties across gastrointestinal, musculoskeletal, and neurological systems[1][2]. TB-500 (Thymosin β4) is a 43-amino-acid peptide involved in cell migration, angiogenesis, and wound healing[3][4]. This blend combines both peptides for synergistic tissue-repair research applications.

Related research: For distinct compound, component, or formulation evidence and safety context, read BPC-157 Peptide: Benefits, Uses, Side Effects, Dosage, and Research and TB-500 Peptide: Benefits, Uses, Side Effects, Dosage, and Research. These links are comparisons only; the compounds and formulations should not be treated as interchangeable.

Standard / Gradual Approach (3 mL = ~6.67 mg/mL total)

Route: Subcutaneous injection | Frequency: Once daily

Weeks 1–2

500 mcg (0.5 mg)

~250 mcg each

7.5 units (0.075 mL)

Weeks 3–4

666 mcg (0.67 mg)

~333 mcg each

10 units (0.10 mL)

Weeks 5–8

1,000 mcg (1.0 mg)

~500 mcg each

15 units (0.15 mL)

For ≤10-unit (≤0.10 mL) administrations during Weeks 1–4, consider using 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.

Inject slowly down the vial wall; avoid foaming or direct stream onto the powder.

Gently swirl or roll until fully dissolved (do not shake).

Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Advanced / Loading Phase (Optional)

Some protocols use a higher TB-500 loading dose during the first 2–4 weeks based on clinical monograph recommendations[5]. This schedule uses higher total blend volumes.

Route: Subcutaneous injection | Frequency: Once daily or split twice weekly for TB-500 loading

Loading (Weeks 1–4)

1,500 mcg (1.5 mg)

~750 mcg each

22.5 units (0.225 mL)

Maintenance (Weeks 5–8)

Note: Advanced protocols consume peptide supplies faster. Plan vial quantities accordingly.

Supplies Needed

Plan based on a 4–8 week daily protocol (standard approach at ~1 mg/day maintenance).

Peptide Vials (BPC-157 + TB-500 20 mg Blend):

4 weeks (28 doses at ~0.67–1.0 mg/day): 2 vials

6 weeks (42 doses): 3 vials

8 weeks (56 doses): 3–4 vials

Insulin Syringes (U-100):

Per week: 7 syringes (1/day)

4 weeks: 28 syringes

6 weeks: 42 syringes

8 weeks: 56 syringes

Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.

4 weeks (2 vials): 6 mL → 1 × 10 mL bottle

6 weeks (3 vials): 9 mL → 1 × 10 mL bottle

8 weeks (4 vials): 12 mL → 2 × 10 mL bottles

Alcohol Swabs: One for the vial stopper + one for the injection site each day.

Per week: 14 swabs (2/day)

4 weeks: 56 swabs → recommend 1 × 100-count box

6 weeks: 84 swabs → recommend 1 × 100-count box

8 weeks: 112 swabs → recommend 2 × 100-count boxes

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

STORAGE

Combined Storage Considerations

Both lyophilized peptides remain stable at refrigeration temperatures (2-8°C) for up to 6 months. Once reconstituted, each solution should be used within 28-30 days, refrigerated, and protected from light. Repeated freeze-thaw cycles degrade peptide integrity and should be avoided. Co-administered protocols share the same storage handling — there are no additional storage requirements specific to the combination beyond the standard precautions for each component. See the peptide storage guide for detailed parameters.
02

Question drills

Open a question for its connected answer.

01What If You Need Higher BPC-157 Doses Without Increasing TB-500 or KPV?+

You cannot independently scale BPC-157 in Wolverine Stack. If your tendon repair model requires 1mg BPC-157 daily based on dose-response data, increasing Wolverine Stack administration to reach that dose simultaneously delivers 1mg TB-500 and 250mcg KPV. Far above established research ranges for those peptides. The only solution is supplementing with standalone BPC-157 alongside Wolverine Stack, which defeats the formulation's logistical purpose entirely. Separate peptides allow precise BPC-157 escalation (500mcg → 1mg) while holding TB-500 and KPV constant.

SOURCE / realpeptides.co ↗
02What If Preliminary Results Show No Synergy?+

Review administration timing and verify peptide purity before concluding failure. Synergy depends on temporal alignment—if BPC-157 peaks when inflammatory cytokines haven't yet upregulated, or TB-500 is administered after the angiogenic window closes, the peptides act independently. Most effective stacking protocols start both peptides within 24 hours of surgical intervention. Real Peptides provides third-party purity verification with every batch—mass spectrometry confirms exact sequencing, critical when research reproducibility depends on molecular precision.

SOURCE / realpeptides.co ↗
03What If I Start the Peptide Stack Before Surgery Instead of After?+

Administer BPC-157 and TB-500 in the 2–4 weeks between injury and surgical reconstruction if the timeline allows. Pre-surgical peptide use reduces baseline inflammation and may improve graft integration by priming the tissue microenvironment for repair. Some surgeons report cleaner surgical fields and less reactive synovitis in patients who've used BPC-157 pre-op. Dosing remains the same: 250–500mcg BPC-157 daily, 2–5mg TB-500 twice weekly. Stop both peptides 48 hours before surgery to avoid theoretical (though undocumented) interactions with anesthesia or clotting.

SOURCE / realpeptides.co ↗
04What If the Wolverine Stack Is Significantly Cheaper — Does That Change the Calculation?+

Only if convenience is the primary variable. If the combined formulation costs less per milligram than separate vials from the same supplier at equivalent purity, and your research model doesn't require phase-specific adjustments, the Wolverine stack becomes defensible. Verify peptide purity via third-party HPLC testing before relying on price alone. Lower cost sometimes reflects lower purity rather than supplier efficiency. Our experience shows that when comparing certified 98%+ purity sources, separate vials typically cost less per milligram; the Wolverine premium reflects packaging convenience, not peptide quality.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

for sale bpc-157 tb-500 research peptide

Methodologically, published studies frequently emphasize rigorous controls and validated assays to isolate peptide-specific effects. When BPC-157/TB-500 is combined with complementary research tools, investigators often test for additivity or pathway selectivity. Any observed changes are reported as laboratory findings rather than clinical recommendations.

RESEARCH

What Do Acute Toxicity Studies in Rodents Actually Show?

The single most-repeated safety claim about BPC-157 is that researchers have been unable to establish a lethal dose. In the terminology of classical toxicology, no reliable LD50 (the dose lethal to half of a test population) has been reported, and a comprehensive review from the originating research group states plainly that even a lethal dose 1 (LD1) “could not be obtained.”[4] Across published efficacy work, BPC-157 has been administered over an extraordinarily wide dose range — from micrograms per kilogram up into the milligram-per-kilogram range — by intragastric, intraperitoneal, intramuscular, and intravenous routes, without the acute mortality that would allow a median lethal dose to be calculated. On its face this is reassuring: a compound with a very high acute margin is a compound unlikely to kill an animal outright at any plausible experimental dose. But three caveats must travel with that statement. First, an unobtainable LD50 is not unique to safe compounds; it simply means the tested doses did not reach a lethal threshold, which can also reflect solubility limits, injection-volume limits, or a decision not to push doses higher. Second, acute lethality is the crudest possible toxicology endpoint — it says nothing about organ injury, immunogenicity, carcinogenicity, or reproductive harm that emerges below the lethal ceiling or over longer exposure. Third, the absence of a lethal dose has largely been documented within efficacy experiments rather than in dedicated acute-toxicity studies conducted to a formal protocol. A high acute margin is a genuine data point, but it is the beginning of a safety assessment, not the conclusion of one. It is also worth resisting a common quantitative leap. A wide gap between an effective dose and the highest dose tested does not straightforwardly translate into a wide human margin of safety, because interspecies scaling of peptides is not a simple body-weight multiplication. Differences in metabolism, plasma peptidase activity, immune recognition, and receptor-pathway sensitivity mean a dose harmless in a rat cannot be assumed harmless, on a per-kilogram basis, in a person. The unobtainable LD50 tells us the acute ceiling is high in the tested species; it does not license a numerical human safety factor, and any framing that converts “no lethal dose in rodents” into “very safe in humans” is smuggling in an inference the data do not support. For TB-500 specifically, comparable dedicated acute-toxicity data are thinner still. The acute-tolerability inferences generally rest on full-length thymosin beta-4, which was reported to be well tolerated in early-phase human dosing (discussed below), rather than on the synthetic fragment. This is a recurring theme: the acute-safety story for the “TB-500” label borrows heavily from a different, better-studied molecule.

POTENTIAL BENEFITS

What Are the Benefits of BPC-157 / TB-500?

By combining localized and systemic regenerative support, BPC-157 / TB-500 may offer several wellness-focused benefits, including:
05

Product & matchup locker

Linked catalog and comparison files.

Comparison

BPC-157 vs. TB-500: A Head-to-Head Comparison

To truly understand what BPC-157 and TB-500 are used for, it helps to see their characteristics side-by-side. While both are studied for recovery, their approaches are fundamental…

Continue reading

Related articles